A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Multiple Sclerosis
In brief
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
Key facts
- Study ID
- NCT00035529
- Run by
- Bristol-Myers Squibb
- Starts
- 2001-11-01
- Expected to finish
- 2003-12-01
- Last updated by the study team
- 2010-12-06
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Local Institution — New Haven, Connecticut, United States
- Local Institution — Louisville, Kentucky, United States
- Local Institution — Worcester, Massachusetts, United States
- Local Institution — Newark, New Jersey, United States
- Local Institution — New York, New York, United States
- Local Institution — Charlotte, North Carolina, United States
- Local Institution — Philadelphia, Pennsylvania, United States
- Local Institution — Dallas, Texas, United States
- Local Institution — Burlington, Vermont, United States
- Local Institution — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.